About us

We are committed to providing innovative solutions for diagnosing infectious diseases and aim to increase the availability of high-quality vaccines in order to combat the spread of infectious diseases globally.

Beijing Wantai Biological Pharmacy is one of the leading manufacturers in China of infectious disease diagnostics and a global leader in Hepatitis E diagnostics.

Founded in 1991, Beijing Wantai has grown from a small laboratory to one of the biggest and most influential Chinese manufacturers of in vitro diagnostic tests and is leading the way in blood transfusion and infectious immunology.

As Asia-Pacific’s largest HIV diagnostic reagent production base we have dominated the reagent market for the past 15 years; our Hepatitis C and Syphilis detection reagents have been top products in the market for several years.

At Beijing Wantai we are specialised in manufacturing ELISA kits and rapid tests for infectious disease diagnostics, producing and distributing chemiluminescence and clinical chemistry reagents, and researching – as well as manufacturing – quality control materials.

We service both international and domestic customers including blood banks, hospitals and clinics, reference laboratories, border inspection centres, blood-processing companies, and research institutes.

Our headquarters are located in the biotechnology heart of Beijing at Zhongguancun Life Science Park Beijing.

Our Beijing plant is the largest manufacturing base for the production of immunodiagnostic reagents in China. Our state-of-the-art production facilities are GMP, ISO9001 and ISO13485 certified and our products undergo strict quality and cost controls. Most of our products bear the CE marking including our HCV, HBsAg and HIV ELISA kits. Our HIV Rapid test and HIV ELISA kit are WHO pre-qualified ensuring that that test kits can be used globally where they are needed.

Beijing Wantai is the biopharma arm of Yangshengtang Group and employs more than 1000 people.

2020

IPO in Shanghai Stock Exchange. Stock Code SH.603392

2020

Wantai launched one molecular and 3 serology COVID-19 tests

2019

HIV Urine self-test launched in China

2019

Innovax received New Drug Certificate for Cecolin® Recombinant HPV Vaccine.

2017

CARIS CLIA automated platform launch

2016

Wantai HIV Rapid Test and HIV ELISA PQ-ed by WHO

Founded in 2005, Xiamen Innovax Biotech CO., LTD. (INNOVAX) is dedicated to developing innovative vaccines.

Xiamen Innovax Biotech Co., Ltd. (INNOVAX) is a subsidiary of Wantai and is a leading company in the field of developing, manufacturing and marketing innovative vaccines with its headquarter and manufacture facilities based in Xiamen, China. In collaboration with the National Institute of Diagnostics and Vaccine Development in Infectious Diseases (NIDVD) of Xiamen University, Innovax has established a core-platform using DNA recombinant technology to express protein in E. coli for vaccine production. Based on this platform, the world’s first hepatitis E vaccine, Hecolin® was launched in China in October 2012.

We have also developed two vaccines against HPV: Cecolin® (approved in China in December 2019) and Cecolin 9™ (clinical trial approved). Furthermore, preclinical studies are in progress for a vaccine against Rotavirus as well as a Recombinant Hepatitis B Protein Injection.

26

Years of Experience

1000

Employees

35

Diagostic Tests

Would you like to know more about what we do?

Don't hesitate to contact us if you would like to find out more about our diagnostic tests and vaccines

Contact Us

2020 - Wantai BioPharm. All Rights Reserved. Designed & Developed by SweeneyVesty Studio